Predictors of prophylactic response to lithium;Prédicteurs de réponse prophylactique au lithium

Encephale

Volumn 34, Issue 4, 2008, Pages 394-399

  Rohayem, J ^a   Bayle J F ^b   Richa, S ^a  

^a Hôpital Psychiatrique de la Croix   (Lebanon)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Bipolar disorder; Lithium; Mood stabilizer; Predictor; Prophylaxis

Indexed keywords

CREATINE PHOSPHATE; HLA A3 ANTIGEN; ISOENZYME; LITHIUM; MESSENGER RNA; PHOSPHATASE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SEROTONIN; SEROTONIN TRANSPORTER;

ALCOHOL ABUSE; ARTICLE; BIPOLAR DISORDER; CALCIUM MOBILIZATION; COMORBIDITY; DISEASE COURSE; DRUG ABUSE; ELECTROENCEPHALOGRAPHY; ERYTHROCYTE MEMBRANE; EVOKED AUDITORY RESPONSE; FAMILY HISTORY; LITHIUM BLOOD LEVEL; MIXED MANIA AND DEPRESSION; MOOD DISORDER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROPHYLAXIS; TREATMENT RESPONSE; WHITE MATTER;

5'-NUCLEOTIDASE; ANTIMANIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BLOOD PLATELETS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LITHIUM CARBONATE; PROSPECTIVE STUDIES; RNA, MESSENGER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; SOCIAL ENVIRONMENT; SUBSTANCE-RELATED DISORDERS; TRYPTOPHAN HYDROXYLASE;

EID: 52049115246     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2007.05.002     Document Type: Article

References (40)

1. Aagaard J., and Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord 18 (1990) 259-266
2. Atack J.R., Broughton H.B., and Pollack S.J. Inositol monophosphatase: a putative target for Li + in the treatment of bipolar disorder. Trends Neurosci 18 (1995) 343-349
3. Baldessarini R., Tondo L., Floris G., and Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord 61 (2000) 13-22
4. Baldessarini R., Tondo L., and Viguera A. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord 1 (1999) 17-24
5. Bauer M.S., and Mitchner L. What is a mood "stabilizer"? An evidence-based response. Am J Psychiatry 161 1 (2004) 3-18
6. Bowden C., Calabrese J.R., McElroy S.L., et al. A randomized, placebo controlled 12-month trial of divalproex and lithium in treatment of out-patients with bipolar I disorder. Arch Gen Psychiatry 57 (2000) 481-489
7. Buchsbaum M., Goodwin F., Murphy D., and Borge G. AER in affective disorders. Am J Psychiatry 128 (1971) 19-25
8. Calabrese J.R., Fatemi S.H., et al. Predictors of response to mood stabilizers. J Clin Psychopharmacol 16 suppl 1 (1996) 24-31
9. Del Vecchio M., Farzati B., Maj M., et al. Cell membrane predictors of response to lithium prophylaxis of affective disorders. Neuropsychobiology 7 (1981) 243-247
10. Dimitrova A., Milanova V., et al. Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment. Pharmacogenomics J 5 1 (2005) 35-41
11. Dunner D.L., and Fieve R.R. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30 (1974) 229-233
12. Gay C. Pratiques de la lithiothérapie : consensus et controverses (1997), Doin éditeur, Paris pp. 91-101
13. Greil W., Ludwig-Mayerhofer W., Erazo N., et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders- a randomized study. J Affect Disord 43 (1997) 151-161
14. Grof P., Hux M., Grof E., et al. Prediction of response to stabilizing lithium treatment. Pharmacopsychiatria 16 (1983) 195
15. Hegerl U., Galliant J., and Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?. J Affect Disord 62 (2001) 93-100
16. Himmelhoch J., Mulla D., Neil J., Detre T., and Kupfer D. Incidence and significance of mixed affective states in a bipolar population. Arch Gen Psychiatry 33 (1976) 1062-1066
17. Ikeda A., and Kato T. Biological predictors of lithium response in bipolar disorder. Psychiatr and Clin Neurosci 57 (2003) 243-250
18. 31P-MRS in bipolar disorder. Intern J Neuropsychopharmacol 3 (2000) 83-85
19. Keck P., and McElroy S. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry 63 suppl 10 (2002) 13-17
20. Knorring L., Oreland L., Perris C., and Wiberg A. Evaluation of the lithium RBC/plasma ratio as a predictor of the prophylactic effect of lithium treatment in affective disorders. Pharmakopsychiatr Neuropsychopharmakol 9 (1976) 81-84
21. Koukopoulos A., Reginaldi D., Minnai G., Serra G., Pani L., and Johnson F.N. The long term prophylaxis of affective disorders. Adv Biochem Psychopharmacol 49 (1995) 127-147
22. Kusalic M., and Engelsmann F. Predictors of lithium treatment responsiveness in bipolar patients: a two-year prospective study. Neuropsychobiology 37 (1998) 146-149
23. Layden B.T., Minadeo N., Suhy J., Abukhdeir A.M., Metreger T., Foley K., Borge G., Crayton J.W., Bryant F.B., and Mota de Freitas D. Biochemical and psychiatric predictors of Li+ response and toxicity in Li+ - treated bipolar patients. Bipolar Disord 6 (2004) 53-61
24. Maj M. The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord 5 (2003) 180-188
25. Mendels J., and Frazer A. Intracellular lithium concentration and clinical response. Towards a membrane theory of depression. J Psychiatr Res 10 (1973) 9-18
26. Mendlewicz J., Fieve R., and Stallone F. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry 130 (1973) 1011-1013
27. Nemanov L., Ebstein R., Belmaker R.H., Osher Y., and Agam G. Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. Int J Neuropsychopharmacol 2 (1999) 25-29
28. Perris C., Strandman E., and Wahlby L. HLA antigens and the response to prophylactic lithium. Neuropsychobiology 5 (1979) 114-118
29. Prien R., Himmelhoch J., and Kupfer D. Treatment of mixed mania. J Affect Disord 15 (1988) 9-15
30. Reeves R.R., Struve F.A., and Patrick G. Does EEG predict response to valproate versus lithium patients with mania?. Ann Clin Psychiatry 13 (2001) 69-73
31. Secunda S., Katz M., Swann A., Koslow S., Maas J., Chuang S., and Croughan J.M. Diagnosis, state measurement and prediction of treatment response. J Affect Disord 8 (1985) 113-121
32. Serretti A., Lattuada E., Franchini L., and Smeraldi E. Melancholic features and response to lithium prophylaxis in mood disorders. Depress anxiety 11 (2000) 73-79
33. Serretti A., and Artioli P. Predicting response to lithium in mood disorders: role of genetic polymorphisms. Am J Pharmacogenomics 3 1 (2003) 17-30
34. Small J., Milstein V., Malloy F., Klapper M., Golay S., and Medlock C. Topographic EEG studies of mania. Clin Electroencephalogr 29 (1998) 59-66
35. Suzuki K., Kusumi I., Sasaki Y., and Koyoma T. Serotonin-induced platelet intracellular calcium mobilization in various psychiatric disorders: is it specific to bipolar disorder?. J Affect Disord 64 (2001) 291-296
36. Taylor R., Mallinger A.G., Franck E., Rucci P., Thase M.E., and Kupfer D.J. Variability of erythrocyte and serum lithium levels correlate with therapist treatment adherence efforts and maintenance treatment outcome. Neuropsychopharmacology 24 (2001) 192-197
37. Tondo L., Baldessarini R., Hennen J., Floris G., Silvetti F., and Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 59 (1998) 405-414
38. Yazici O., Kora K., Üçok A., Tunali D., and Turan N. Predictors of lithium prophylaxis in bipolar patients. J Affect Disord 55 (1999) 133-142
39. Yoon I.S., Li P.P., Siu K.P., et al. Altered IMPASE2 gene expression and calcium homeostasis in bipolar disorder. Mol Psychiatry 6 (2001) 678-683
40. Zvolsky P., Dvorakova M., Vinarova E., et al. Proceedings: genetic aspects of lithium ratio in red blood cells and in plasma of manic- depressive patients. Act Nerv Super (Praha) 17 (1975) 271-272